Compare Recursion Pharmaceuticals Inc (RXRX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Verizon Communications Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while Verizon Communications Inc trades at $43.76 (market cap $181.64B). The key difference: Verizon Communications Inc is far larger — about 118.7× Recursion Pharmaceuticals Inc's market cap, and Verizon Communications Inc pays a 6.51% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | VZ | |
|---|---|---|
Market Cap | $1.53B | $181.64B |
Sector | Health | Media |
52-Week High | $6.79 | $51.38 |
52-Week Low | $2.84 | $38.40 |
Enterprise Value | $946.50M | $369.14B |
Volume | — | 22,584,735 |
Dividend Yield | — | 6.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Verizon (VZ) trades at $43.78, up 0.44% today, with a bearish technical signal but strong fundamentals including a P/E of 10.61 and consistent earnings beats. Recent news highlights a restructuring involving 3,000 job cuts and the sale of 274 stores to franchisees, aimed at boosting efficiency ahead of Q2 2026 earnings. Cash flow improved in 2025 with net cash flow of $14.9 billion, supporting its 6.5% dividend yield.
Outlook: Attractive for income investors due to stable cash flows and high dividend, but faces risks from 5G competition and margin pressure. Analyst consensus price target is $47.83, suggesting upside potential if execution improves. Key risks include debt levels and industry discounts threatening profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
